Enhanced IL36RN Expression and Its Association With Immune Microenvironment Predicts Poor Prognosis in Gastric Cancer

IF 3.1 2区医学 Q2 ONCOLOGY

Cancer Medicine Pub Date : 2025-05-10 DOI:10.1002/cam4.70954

Xiaojing Zhang, Sutian Jiang, Hang Yin, Hui Zhang, Lei Yang, Pingping Sun, Xiaoling Kuai, Chen Chen, Jianfei Huang

{"title":"Enhanced IL36RN Expression and Its Association With Immune Microenvironment Predicts Poor Prognosis in Gastric Cancer","authors":"Xiaojing Zhang, Sutian Jiang, Hang Yin, Hui Zhang, Lei Yang, Pingping Sun, Xiaoling Kuai, Chen Chen, Jianfei Huang","doi":"10.1002/cam4.70954","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>Gastric cancer (GC) remains a prevalent and lethal malignancy worldwide, underscoring the urgent need to identify novel therapeutic targets and elucidate the tumor microenvironment (TME) to enhance clinical outcomes.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>IL36RN mRNA expression in GC tissues was analyzed using The Cancer Genome Atlas (TCGA) dataset. Bioinformatics approaches, cellular models, and clinical tissue microarrays were employed to investigate the functional role of IL36RN, its interactions within the TME, and its prognostic significance.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>IL36RN expression was markedly upregulated in GC tissues and associated with unfavorable survival outcomes. Functional assays demonstrated that IL36RN silencing suppressed GC cell proliferation and invasion. Elevated IL36RN expression correlated with enhanced CD8<sup>+</sup> T cell infiltration in the TME and served as an independent prognostic indicator in GC.</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>IL36RN represents a potential prognostic biomarker and therapeutic target in GC, offering novel avenues for precision oncology and immunotherapeutic intervention.</p>\n </section>\n </div>","PeriodicalId":139,"journal":{"name":"Cancer Medicine","volume":"14 9","pages":""},"PeriodicalIF":3.1000,"publicationDate":"2025-05-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cam4.70954","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Medicine","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/cam4.70954","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background

Gastric cancer (GC) remains a prevalent and lethal malignancy worldwide, underscoring the urgent need to identify novel therapeutic targets and elucidate the tumor microenvironment (TME) to enhance clinical outcomes.

Methods

IL36RN mRNA expression in GC tissues was analyzed using The Cancer Genome Atlas (TCGA) dataset. Bioinformatics approaches, cellular models, and clinical tissue microarrays were employed to investigate the functional role of IL36RN, its interactions within the TME, and its prognostic significance.

Results

IL36RN expression was markedly upregulated in GC tissues and associated with unfavorable survival outcomes. Functional assays demonstrated that IL36RN silencing suppressed GC cell proliferation and invasion. Elevated IL36RN expression correlated with enhanced CD8⁺ T cell infiltration in the TME and served as an independent prognostic indicator in GC.

Conclusions

IL36RN represents a potential prognostic biomarker and therapeutic target in GC, offering novel avenues for precision oncology and immunotherapeutic intervention.

Abstract Image

查看原文本刊更多论文

IL36RN表达增强及其与免疫微环境的关联预测胃癌不良预后

背景胃癌（GC）仍然是世界范围内普遍存在的致死性恶性肿瘤，因此迫切需要确定新的治疗靶点并阐明肿瘤微环境（TME）以提高临床疗效。方法利用美国癌症基因组图谱（TCGA）数据集分析胃癌组织中IL36RN mRNA的表达。采用生物信息学方法、细胞模型和临床组织微阵列来研究IL36RN的功能作用、其在TME中的相互作用及其预后意义。结果IL36RN在胃癌组织中的表达明显上调，并与不良的生存结果相关。功能分析表明IL36RN沉默抑制GC细胞的增殖和侵袭。IL36RN表达升高与TME中CD8+ T细胞浸润增强相关，可作为GC的独立预后指标。结论IL36RN是一种潜在的胃癌预后生物标志物和治疗靶点，为精准肿瘤学和免疫治疗干预提供了新的途径。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cancer Medicine ONCOLOGY-

CiteScore

5.50

自引率

2.50%

发文量

907

审稿时长

19 weeks

期刊介绍： Cancer Medicine is a peer-reviewed, open access, interdisciplinary journal providing rapid publication of research from global biomedical researchers across the cancer sciences. The journal will consider submissions from all oncologic specialties, including, but not limited to, the following areas: Clinical Cancer Research Translational research ∙ clinical trials ∙ chemotherapy ∙ radiation therapy ∙ surgical therapy ∙ clinical observations ∙ clinical guidelines ∙ genetic consultation ∙ ethical considerations Cancer Biology: Molecular biology ∙ cellular biology ∙ molecular genetics ∙ genomics ∙ immunology ∙ epigenetics ∙ metabolic studies ∙ proteomics ∙ cytopathology ∙ carcinogenesis ∙ drug discovery and delivery. Cancer Prevention: Behavioral science ∙ psychosocial studies ∙ screening ∙ nutrition ∙ epidemiology and prevention ∙ community outreach. Bioinformatics: Gene expressions profiles ∙ gene regulation networks ∙ genome bioinformatics ∙ pathwayanalysis ∙ prognostic biomarkers. Cancer Medicine publishes original research articles, systematic reviews, meta-analyses, and research methods papers, along with invited editorials and commentaries. Original research papers must report well-conducted research with conclusions supported by the data presented in the paper.